FDA Accepts Larotrectinib New Drug Application and Grants Priority Review
May 29, 2018 06:45 ET
|
Loxo Oncology, Inc.
– PDUFA date set for November 26, 2018 – STAMFORD, Conn., May 29, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly...
Loxo Oncology Announces Details of LOXO-292 Clinical Data Presentations at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
May 16, 2018 17:00 ET
|
Loxo Oncology, Inc.
– LOXO-292 Phase 1 Clinical Trial Abstract Selected for “Best of ASCO” – – Company to Host Conference Call and Webcast on Saturday, June 2nd at 4:00 p.m. CT – STAMFORD, Conn., May 16, 2018 (GLOBE...
Loxo Oncology Reports First Quarter 2018 Financial Results
May 08, 2018 06:45 ET
|
Loxo Oncology, Inc.
- LOXO-292 Phase 1 Oral Presentation Upcoming at 2018 ASCO Annual Meeting - - LOXO-292 Preclinical and Clinical Proof-of-Concept Data Published in Annals of Oncology - - Rolling Submission for...
Loxo Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 07, 2018 16:30 ET
|
Loxo Oncology, Inc.
STAMFORD, Conn., May 07, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with...
Loxo Oncology to Announce First Quarter 2018 Financial Results
May 01, 2018 06:45 ET
|
Loxo Oncology, Inc.
STAMFORD, Conn., May 01, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with...
Loxo Oncology and Illumina to Partner on Developing Next-Generation Sequencing-Based Pan-Cancer Companion Diagnostics
April 10, 2018 06:45 ET
|
Loxo Oncology, Inc.
- Expands Illumina’s Oncology Offerings for NextSeq™ 550Dx with a Companion Diagnostic Version of TruSight™ Tumor 170 for Solid Tumors - - Loxo Oncology to Utilize a Companion Diagnostic Version of...
Loxo Oncology Announces Acceptance of LOXO-292 Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting
April 04, 2018 06:45 ET
|
Loxo Oncology, Inc.
STAMFORD, Conn., April 04, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with...
Loxo Oncology Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Larotrectinib for the Treatment of TRK Fusion Cancer
March 26, 2018 06:45 ET
|
Loxo Oncology, Inc.
STAMFORD, Conn., March 26, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with...
Loxo Oncology to Present at the Cowen and Company 38th Annual Health Care Conference
March 06, 2018 06:45 ET
|
Loxo Oncology, Inc.
STAMFORD, Conn., March 06, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with...
Loxo Oncology Reports Fourth Quarter and Year-End 2017 Financial Results
March 01, 2018 06:45 ET
|
Loxo Oncology, Inc.
– Larotrectinib Rolling NDA Submission on Track for Completion in March – – LOXO-292 Phase 1 Clinical Data Update Expected in First Half 2018 – STAMFORD, Conn., March 01, 2018 (GLOBE NEWSWIRE) --...